*Division of Hepatology, Baylor Simmons Transplant Institute, Fort Worth, TX
†Icahn School of Medicine at Mt. Sinai, New York
‡Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine, State University of New York at Buffalo, Buffalo, NY
Research reported in this article was partially funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (IHS-1507-31640), the Troup Fund of the Kaleida Health Foundation, the Chronic Liver Disease Foundation, and through unrestricted educational grants from Merck, AbbVie, and Gilead Sciences. The statements in this article are solely the responsibility of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors, or Methodology Committee.
S.A.G.: Speaker’s Bureau—AbbVie, Gilead, Merck; Advisory board—AbbVie. D.S.F.: reports owning stock in Gilead Sciences. A.H.T.: Grant/Research Support—Merck, Gilead, Abbott, AbbVie, Intercept, Tobira, Conatus; Committee/Advisor—Merck, Abbott Diagnostics, AbbVie, Chronic Liver Disease Foundation; Speaker’s Bureau—Chronic Liver Disease Foundation.
Reprints: Andrew H. Talal, MD, MPH, Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine, State University of New York at Buffalo, 875 Ellicott Street, Suite 6089, Buffalo, NY 14203 (e-mail: [email protected]).